C4 Therapeutics Q2 FY26 net loss narrows to $23.6 million; revenue rises to $6.6 million

Reuters2026/08/11 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

C4 Therapeutics posted Q2 revenue of USD 6.6 million, up 1.54% year over year, helped by revenue recognized under its new Roche DAC collaboration.
Net loss narrowed to USD 23.6 million; loss per share improved to USD 0.18.
RD expense fell 6.49% to USD 24.5 million; GA expense eased 2.27% to USD 8.6 million, both on lower stock-based compensation.
Cash, cash equivalents and marketable securities rose to USD 300.4 million, reflecting USD 33.5 million of ATM proceeds and a USD 20 million Roche upfront payment.
Phase 2 MOMENTUM enrollment remains on track to finish in Q1 2027; initial ORR data expected in 2H 2027, with additional cemsidomide combination updates slated for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807425) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs Asia-Pacific Chief Equity Strategist Timothy Moe maintains a KOSPI target of 12,000 points, implying an almost 80% increase from the current level. He points out that the market is systematically underestimating the sustainability of the AI storage chip profit cycle. Capital expenditures by US tech giants may exceed $1.2 trillion next year, and the chip shortage triggered by data center expansion will further intensify in 2027. The current KOSPI is trading at only 5.3 times expected earnings, about half of its historical average.

华尔街见闻•2026/09/07 01:26

Norwegian sovereign wealth fund may cut $80 billion US Treasury holdings; high-rated mortgage securities expected to become new favorites

Norway's sovereign wealth fund, with a scale of $2.3 trillions, has recommended reducing government bond holdings and reallocating funds towards higher-yielding fixed income assets.

智通财经•2026/09/07 01:21